An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 6
- Sponsors Bayer
- 29 Aug 2017 Accrding to a Bayer media release, first U.S. patient ha been enrolled.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.
- 20 Jun 2017 New trial record